Please reference the list below for active Phase I/Translational clinical research being conducted by Comprehensive Cancer Centers.

i2473 Phase Ia/Ib Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of Ro7198457 As A Single Agent And In Combination With Atezolizumab In Patients With Locally Advanced Or Metastatic Tumors
17087 An Open-Label, Multicenter Extension Study In Patients Previously Enrolled In A Genentech And/Or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study **SURVIVAL ONLY ENROLLMENT OPEN**
i2544 A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination with Durvalumab in Patients with Advanced Solid Malignancies **ON HOLD**
17212 A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) **CALL PROJECT MANAGER- NO SLOTS AVAILABLE**
i2570 A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors **ENROLLMENT ON HOLD**
i2600 An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts **OPEN TO COHORT D1 ONLY**
18232 A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies **CALL PROJECT MANAGER; DOSE EXPANSION OPEN IN ARM 1 AND 4**
i2644 A phase 1, open-label, dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in subjects with metastatic castration-resistant prostate cancer who have progressed on at least two prior systemic therapies
18188 A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors **ON HOLD**
18194 A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRá) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers **ON HOLD**
i2656 A Phase 1/2 Multi-Center Investigation Of ABI-009 (Nab-Rapamycin) In Combination With FOLFOX And Bevacizumab As First-Line Therapy In Patients With Advanced Or Metastatic Colorectal Cancer
i2686 A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)
i2710 A Phase I, Open-Label Single-Dose Pharmacokinetic And Safety Study Of Oral Tazemetostat In Subjects With Moderate And Severe Hepatic Impairment With Advanced Malignancies
i2648 Phase 1/2 Dose Escalation And Dose Expansion Study Of Ba3011 In Patients With Advanced Solid Tumors
19082 A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers **CALL PROJECT MANAGER: COHORT 2A AND 2B- PAUSED, 1C-PAUSED, 1D-PAUSED- NO SLOTS AVAILABLE**
i2747 A Phase 1b/2 Open-Label Study Evaluating Tazemetostat In Combination With Enzalutamide Or Abiraterone/Prednisone In Chemotherapy Naive Subjects With Metastatic Castration Resistant Prostate Cancer
i2717 A Phase I, Open-Label, Dose Findings, First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 when Administered with Enzalutamide, Abiraterone, or Apalutamide in Subjects with Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
i2764 A Phase 1b Dose-Finding Study of ARO-HIF2 in Patients with Advanced Clear Cell Renal Cell Carcinoma
i2774 A Phase I, First-In-Human, Multicenter, Open-Label Study of ABM-1310, Administered Orally in Adult Patients with Advanced Solid Tumors
i2707 A Phase 1 Study of ASP1951 in Subjects with Advanced Solid Tumors
i2788 A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer Protocol for Phase 1 Study of EPI-7386
i2780 A Phase 1/1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1454 alone and in Combination with Ipilimumab and Nivolumab
18164 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)